Biomarkers of response to immune checkpoint blockade in cancer treatment

Academic history of immunity in tumors dates back to 1893 when William Coley, considered the Father of Immunotherapy, reported that sarcoma or cancer patients injected with or infected by bacteria named “Coley’s toxin” showed marked tumor regression 1,2,3. No significant progress was made thereafter as the concept of immunity against cancer cells was much debated and abandoned in preference to chemotherapy and radiation 3, until the theory of cancer immunosurveillance was proposed by Lewis Th omas and Frank Macfarlane Burnet in 1957 4,5.
Source: Critical Reviews in Oncology Hematology - Category: Cancer & Oncology Authors: Source Type: research